Research Overview of the High-Quality Development Status of the Pharmaceutical Industry in China(2021-2023)
Objective:To understand the transition and operational status of China's pharmaceutical industry towards high-quality development since the 14th Five-Year Plan,analyze the influence and role of regulatory policies in this transition,discuss the challenges faced by the industry,and put forward strategic suggestions for further advancement.Methods:Through literature research,surveys,interviews,and expert consultations to obtain relevant policy information,data,industry views,etc.Expert discussion are organized to support the research.Results:China's pharmaceutical industry has actively responded to the economic downward pressure,showing a resilience in industrial development,with significant advancements in new drug evaluation and listing,traditional Chinese medicine development,and regulatory science projects.Conclusion:The pharmaceutical industry in China is actively adjusting deeply towards high-quality development and transformation.At present,positive progress has been made in research and development innovation,manufacturing upgrading and innovation of traditional Chinese medicine.However,there are still challenges in research and development strategy,funding,traditional Chinese medicine inheritance and innovation,internationalization,and supply chain stability.It is recommended to further transform research and development strategies,diversify financing system,improve international supporting policies,reinforce traditional Chinese medicine supervision,deepen regulatory science,strengthen the construction of regulatory capacity,and promote the Tripartite Cooperation of Medical Services to effectively promote the high-quality development of the pharmaceutical industry.
pharmaceutical industryhigh-quality developmentinnovationtraditional Chinese medicinedrug manufacturingregulatory science
万方数据
维普
